{
  "ticker": "JNJ",
  "target_date": "2025-06-02",
  "actual_date": "2025-06-02",
  "collected_at": "2025-12-08T11:50:16.036513",
  "price": {
    "open": 152.39,
    "high": 153.43,
    "low": 150.24,
    "close": 153.2943572998047,
    "volume": 6669300,
    "change_1d_pct": 0.12,
    "change_7d_pct": 2.32,
    "change_30d_pct": -0.47
  },
  "technicals": {
    "rsi_14": 55.92,
    "sma_20": 150.03,
    "sma_50": 151.81,
    "macd": 0.011,
    "macd_signal": -0.668,
    "macd_histogram": 0.679,
    "bb_upper": 155.42,
    "bb_lower": 144.63,
    "price_vs_sma20_pct": 2.18,
    "price_vs_sma50_pct": 0.97,
    "volume_ratio": 0.8
  },
  "fundamentals": {
    "market_cap": 489424191488,
    "pe_ratio": 19.608109,
    "forward_pe": 19.16415,
    "price_to_book": 6.1656604,
    "price_to_sales": 5.3112264,
    "profit_margin": 27.26,
    "operating_margin": 30.2,
    "roe": 33.62,
    "roa": 8.26,
    "revenue_growth": 6.8,
    "earnings_growth": 91.0,
    "debt_to_equity": 57.766,
    "current_ratio": 1.074,
    "quick_ratio": 0.711,
    "dividend_yield": 258.0,
    "fifty_two_week_high": 207.81,
    "fifty_two_week_low": 140.68,
    "fifty_day_avg": 193.4922,
    "two_hundred_day_avg": 170.2741,
    "analyst_target": 203.41833,
    "analyst_recommendation": "buy",
    "num_analysts": 24,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -2.25,
    "pct_from_52w_low": 44.4
  },
  "macro": {
    "spy": {
      "price": 589.33,
      "change_1d_pct": 0.56,
      "change_7d_pct": 1.65
    },
    "vix": {
      "level": 18.36,
      "signal": "NORMAL"
    },
    "treasury_10y": {
      "yield_pct": 4.46
    },
    "dollar_index": {
      "level": 98.7
    },
    "gold": {
      "price": 3370.6
    },
    "regime": "BULL_NORMAL"
  },
  "news": [
    {
      "headline": "Johnson & Johnson (NYSE:JNJ) Unveils Promising Prostate Cancer Data With Pasritamig",
      "source": "Yahoo",
      "datetime": 1748884801,
      "summary": "Johnson & Johnson (NYSE:JNJ) recently announced promising Phase 1 study results for Pasritamig, a novel antibody for advanced prostate cancer, which may have influenced its stock's 1.5% rise last week. The study highlights, including a favorable safety profile and potential efficacy in disease contr",
      "url": "https://finnhub.io/api/news?id=d59436fdb5b748408129dff6b114f16279c1b9c0f1dd375f6cfa24f72ed9d25d"
    },
    {
      "headline": "June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035",
      "source": "SeekingAlpha",
      "datetime": 1748880000,
      "summary": "Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and smart diversification...",
      "url": "https://finnhub.io/api/news?id=1a1690d0d6fa893c1191db6a53ce4c2ce65038e5023a9acbfc5ebed5211df28f"
    },
    {
      "headline": "ASCO25: Johnson & Johnson reports data from Phase I trial of prostate cancer drug",
      "source": "Yahoo",
      "datetime": 1748875326,
      "summary": "The trial enrolled 174 subjects aged 36\u201389 years who had undergone an average of four previous therapies.",
      "url": "https://finnhub.io/api/news?id=540a5afccd313fae55ec21ddf5babf390939c774597cb3d508d5935698c53d87"
    },
    {
      "headline": "Lord Abbett Developing Growth Fund Q1 2025 Commentary",
      "source": "SeekingAlpha",
      "datetime": 1748868780,
      "summary": "The Fund returned -17.65%, reflecting performance at the net asset value of Class I shares with all distributions reinvested for the quarter ended March 31, 2025.",
      "url": "https://finnhub.io/api/news?id=a63404a629040b3ee1dfbeb821589ec1ac714a5cd7b1b3f88d08123c42a9a6a6"
    },
    {
      "headline": "COO Q2 Earnings Signal Growth and Caution: How to Play the Stock?",
      "source": "Yahoo",
      "datetime": 1748868180,
      "summary": "Cooper Companies beats fiscal second-quarter estimates and raises guidance, but faces fertility headwinds and inventory pressures. Is COO still a long-term growth play?",
      "url": "https://finnhub.io/api/news?id=0d7a884c01e39a9cdc171c618cfaaceb69d93db18b5d7c6ee17f3da69b4b4c5b"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "13F-HR",
      "date": "2025-05-07",
      "description": "xslForm13F_X02/primary_doc.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000090445425000238/xslForm13F_X02/primary_doc.xml"
    },
    {
      "form": "4",
      "date": "2025-05-05",
      "description": "xslF345X05/wk-form4_1746479407.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000143/xslF345X05/wk-form4_1746479407.xml"
    },
    {
      "form": "8-K",
      "date": "2025-04-30",
      "description": "jnj-20250424.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000141/jnj-20250424.htm"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877468.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000138/xslF345X05/wk-form4_1745877468.xml"
    },
    {
      "form": "4",
      "date": "2025-04-28",
      "description": "xslF345X05/wk-form4_1745877247.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/200406/000020040625000135/xslF345X05/wk-form4_1745877247.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}